Phase 2 RCT: Inhaled budesonide shows promise for the treatment of early COVID-19

Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial – The Lancet Respiratory Medicine

Commentary: Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19 – The Lancet Respiratory Medicine

Commentary on Twitter

NEW Research— Early administration of inhaled budesonide reduced the likelihood of needing urgent medical care and reduced time to recovery after early #COVID19

RCT from Mona Bafadhel & colleagues https://t.co/6cJogJs7rp pic.twitter.com/C1dhmTcexP

— The Lancet Respiratory Medicine (@LancetRespirMed) April 10, 2021